Fuller & Thaler Asset Management’s Integra LifeSciences IART Stock Holding History

Fuller & Thaler Asset Management’s Portfolio IART Stock Details IART Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$61.7M	Sell	3,436,006 -93,398	-3%	-$1.31M	0.17%	199
2026 Q1	$33.2M	Sell	3,529,404 -106,956	-3%	-$1.17M	0.11%	235
2025 Q4	$45.2M	Sell	3,636,360 -278,078	-7%	-$3.7M	0.15%	211
2025 Q3	$56.1M	Buy	3,914,438 +21,906	+0.6%	+$300K	0.19%	177
2025 Q2	$47.8M	Sell	3,892,532 -29,987	-0.8%	-$435K	0.17%	193
2025 Q1	$86.3M	Sell	3,922,519 -9,760	-0.2%	-$229K	0.34%	101
2024 Q4	$89.2M	Sell	3,932,279 -35,283	-0.9%	-$770K	0.34%	98
2024 Q3	$72.1M	Buy	3,967,562 +2,125,647	+115%	+$49.3M	0.28%	120
2024 Q2	$53.7M	Buy	1,841,915 +1,401,045	+318%	+$41.6M	0.23%	137
2024 Q1	$15.6M	Sell	440,870 -400,189	-48%	-$16M	0.07%	252
2023 Q4	$36.6M	Buy	841,059 +235,565	+39%	+$9.27M	0.19%	156
2023 Q3	$23.1M	Sell	605,494 -56,669	-9%	-$2.38M	0.13%	174
2023 Q2	$27.2M	Sell	662,163 -847,220	-56%	-$40.8M	0.15%	163
2023 Q1	$86.7M	Sell	1,509,383 -3,269	-0.2%	-$184K	0.5%	73
2022 Q4	$84.8M	Buy	1,512,652 +713,454	+89%	+$36.3M	0.54%	65
2022 Q3	$33.9M	Sell	799,198 -556	-0.1%	-$28.5K	0.24%	130
2022 Q2	$43.2M	Sell	799,754 -2,970	-0.4%	-$178K	0.3%	112
2022 Q1	$51.6M	Buy	802,724 +98,702	+14%	+$6.5M	0.31%	111
2021 Q4	$47.2M	Buy	704,022 +109,220	+18%	+$7.39M	0.27%	117
2021 Q3	$40.7M	Buy	594,802 +294,052	+98%	+$20.8M	0.26%	114
2021 Q2	$20.5M	Buy	300,750 +14,554	+5%	+$1.03M	0.13%	150
2021 Q1	$19.8M	Buy	286,196 +1,651	+0.6%	+$112K	0.14%	153
2020 Q4	$18.5M	Buy	284,545 +206,260	+263%	+$11.1M	0.17%	142
2020 Q3	$3.7M	Buy	78,285 +242	+0.3%	+$11.5K	0.05%	244
2020 Q2	$3.67M	Sell	78,043 -67,422	-46%	-$3.31M	0.05%	240
2020 Q1	$6.5M	Buy	145,465 +968	+0.7%	+$50.8K	0.11%	172
2019 Q4	$8.42M	Buy	144,497 +1,395	+1%	+$83K	0.09%	175
2019 Q3	$8.6M	Buy	143,102 +31,449	+28%	+$1.87M	0.1%	167
2019 Q2	$6.24M	Buy	+111,653	New	+$5.75M	0.07%	193

Other funds holding IART

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

PCMI

Paradigm Capital Management Inc Albany, New York $3.67B AUM 121.12% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Fuller & Thaler Asset Management's IART Position: Q2 2026 in Review

Fuller & Thaler Asset Management reduced its Integra LifeSciences (IART) stake by 2.6% in Q2 2026, selling an estimated $1.31M and leaving 3,436,006 shares worth $61.7M. The position accounts for 0.17% of the portfolio, ranked #199.

Fuller & Thaler Asset Management first reported a position in IART in Q2 2019 and has held it in 29 quarters since. The position peaked at $89.2M in Q4 2024. 213 funds tracked by Wall St. Rank hold IART as of Q2 2026.

Fuller & Thaler Asset Management held 3,436,006 shares of Integra LifeSciences worth $61.7M as of Q2 2026.
Fuller & Thaler Asset Management sold 93,398 Integra LifeSciences shares in Q2 2026, an estimated $1.31M.
Integra LifeSciences made up 0.17% of Fuller & Thaler Asset Management's portfolio in Q2 2026, its #199 holding.
Fuller & Thaler Asset Management first reported a position in Integra LifeSciences in Q2 2019 and has held it in 29 quarters since.
Fuller & Thaler Asset Management's Integra LifeSciences position peaked at $89.2M in Q4 2024.
213 funds tracked by Wall St. Rank held Integra LifeSciences as of Q2 2026.

Based on Fuller & Thaler Asset Management's 13F filing for Q2 2026, filed 12 Aug 2026.